Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 1.00 |
| ▸ | CCR3 | P51677 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.67 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.67 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.67 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.67 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.67 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.67 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7407431 | 0.98 | SIGMAR1 (0.97) | SIGMAR1CCR3HRH3KCNH2MEN1 | |
| SCHEMBL8091672 | 0.98 | SIGMAR1 (0.97) | SIGMAR1CCR3HRH3KCNH2MEN1 | |
| SCHEMBL7409408 | 0.95 | SIGMAR1 (0.91) | SIGMAR1CCR3HRH3KCNH2SLC6A2 | |
| Hydrochloric Acid SCHEMBL7404260 | 0.94 | SIGMAR1 (0.88) | SIGMAR1CCR3HRH3KCNH2SLC6A2 | |
| SCHEMBL7372248 | 0.92 | CCR3 (0.84) | SIGMAR1CCR3HRH3KCNH2CYP1A2 | |
| SCHEMBL7403790 | 0.88 | CCR3 (1.00) | SIGMAR1CCR3HRH3SLC6A4PRMT3 | |
| SCHEMBL20306196 | 0.88 | SIGMAR1 (0.78) | SIGMAR1CCR3HRH3KCNH2 | |
| SCHEMBL7404650 | 0.87 | CCR3 (0.76) | SIGMAR1CCR3HRH3 | |
| Hydrochloric Acid SCHEMBL7404097 | 0.87 | CCR3 (0.97) | SIGMAR1CCR3HRH3SLC6A4PRMT3 | |
| SCHEMBL5888786 | 0.86 | SIGMAR1 (0.75) | SIGMAR1CCR3HRH3KCNH2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0869792-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-09-22 | — | — | EP | claimed |
| EP-0869792-A2 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | claimed |
| WO-1997023216-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | claimed |
| EP-0714292-A4 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | CAMBRIDGE NEUROSCIENCE INC (US) | 1996-10-09 | — | — | EP | claimed |
| EP-0714292-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1996-06-05 | — | — | EP | claimed |
| WO-1995000131-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | CAMBRIDGE NEUROSCIENCE, INCORPORATED (US) | 1995-01-05 | — | — | WO | claimed |
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | UMN PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-6124323-A | ACTIVE DRUG TREATING STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMIOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE HEADACHES, CHRONIC PAIN, GLAUCOMA, CMV RETINITIS, PSYCHOSIS | WARNER-LAMBERT COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0869792-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-09-22 | — | — | EP | disclosed |
| EP-0869792-A2 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023216-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | HTR2A, HTR2B, HTR2C | SIGMAR1 314/4885CCR3 1286/4885HRH3 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.